Todd B Sells, Ryan Chau, Jeffrey A Ecsedy, Rachel E Gershman, Kara Hoar, Jessica Huck, David A Janowick, Vivek J Kadambi, Patrick J LeRoy, Matthew Stirling, Stephen G Stroud, Tricia J Vos, Gabriel S Weatherhead, Deborah R Wysong, Mengkun Zhang, Suresh K Balani, Joseph B Bolen, Mark G Manfredi, Christopher F Claiborne
The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective, orally bioavailable inhibitors of Aurora A that have advanced into human clinical trials. Alisertib (10) is currently being evaluated in multiple Phase II and III clinical trials in hematological malignancies and solid tumors.
June 11, 2015: ACS Medicinal Chemistry Letters